Skip to main content

Share story

AI

Anthropic Introduces Claude Import Memory Feature

Switch to Claude without starting over | Claude by Anthropic Image: Primary
Anthropic has introduced a memory import feature for its Claude artificial intelligence system. The tool enables users to transfer preferences and context from other AI providers into Claude. A single copy and paste operation updates the system's memory so that new conversations continue from prior interactions. The process starts when users copy a provided prompt into a chat with any other AI provider. The prompt compiles relevant context into one location. The gathered information is then imported into Claude in under a minute. Claude learns user preferences across conversations. It keeps project contexts separate to prevent information from mixing between tasks. Users can view and edit all stored memories through the system interface. The feature is intended for people who have spent time training another AI and want to switch without losing that context. Individuals can try Claude on the free plan and import memory when ready.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Anthropic and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.